ZHEJIANG WECOME PHARMACEUTICAL COMPANY LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.17 CNY | +0.35% |
|
+0.64% | -32.32% |
| Sales 2021 | 633M 87.35M | Sales 2022 | 531M 73.32M | Capitalization | 3.59B 496M |
|---|---|---|---|---|---|
| Net income 2021 | 96M 13.25M | Net income 2022 | 44M 6.07M | EV / Sales 2021 | 6.39 x |
| Net cash position 2021 | 198M 27.39M | Net Debt 2022 | 156M 21.58M | EV / Sales 2022 | 7.05 x |
| P/E ratio 2021 |
44
x | P/E ratio 2022 |
80
x | Employees | 1,082 |
| Yield 2021 |
1.02% | Yield 2022 |
-
| Free-Float | 24.95% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.35% | ||
| 1 week | +0.64% | ||
| Current month | -10.99% | ||
| 1 month | -12.71% | ||
| 3 months | -19.24% | ||
| 6 months | -25.45% | ||
| Current year | -32.32% |
1 week
16.48
17.35
1 month
15.6720.08
Current year
13.7326.19
1 year
13.7338.23
3 years
13.7338.23
5 years
13.7361.00
10 years
13.7361.00
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Xia Kong
CEO | Chief Executive Officer | 42 | 21-05-16 |
Jing Wang
DFI | Director of Finance/CFO | 37 | 21-05-16 |
Ting Zhu
BRD | Director/Board Member | 35 | 21-05-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bin Wu
BRD | Director/Board Member | 64 | 22-10-09 |
Jiang Feng Liu
BRD | Director/Board Member | 45 | 21-05-16 |
Lan Hao
BRD | Director/Board Member | 56 | 21-05-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 17.17 | +0.35% | 1,041,420 |
| 24-04-23 | 17.11 | +1.24% | 1,219,077 |
| 24-04-22 | 16.9 | -0.82% | 1,122,687 |
| 24-04-19 | 17.04 | +0.06% | 1,484,660 |
| 24-04-18 | 17.03 | -0.18% | 1,503,180 |
End-of-day quote Shenzhen S.E., April 23, 2024
More quotes
Zhejiang Wecome Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of modern Chinese medicine and western medicine. The Company's main products include Yinhuang dripping pills, motherwort soft capsules, motherwort dispersible tablets, Guci capsules, Fengliao Changweikang dispersible tablets, ginseng Jianpi tablets and other Chinese patent medicines, as well as western medicines such as roxithromycin soft capsules. Its production dosage forms cover hard capsules, tablets, granules, soft capsules, and pills. The Company mainly conducts its businesses in the China market.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -32.32% | 343M | |
| +25.61% | 660B | |
| +23.89% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +12.88% | 219B | |
| -9.78% | 196B | |
| +6.79% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 300878 Stock
